The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 21 of the 72 sources its claims cite were checked for support.
Muscle loss and GLP-1R agonists use
Open accessAbstract
Skeletal muscle wasting is a major yet often overlooked determinant of adverse outcomes in diabetes mellitus and obesity. Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk. The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection. However, clinical trials and real-world evidence consistently show that weight reduction with GLP-1RAs is accompanied by decrease in lean body mass, raising concern in patients already predisposed to muscle wasting and underscoring the need for integrated management strategies. By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy. It further examines preventive and therapeutic strategies to preserve muscle health during pharmacological weight loss, with the ultimate aim of providing clinicians and researchers with practical insights and future directions to maximize the benefits of GLP-1RAs while mitigating the risk of sarcopenia.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes evidence on skeletal muscle loss during GLP-1 receptor agonist therapy in type 2 diabetes and obesity, concluding that lean mass loss is proportional to total weight loss and not clearly disproportionate versus other weight-loss approaches, but clinically meaningful sarcopenia risk remains undefined. It outlines monitoring, protein intake, resistance exercise, and emerging anabolic/anti-catabolic pharmacotherapies to preserve muscle during GLP-1RA treatment.
Key findings
- In type 2 diabetes, sarcopenia prevalence ranges from 7% to 29%; in obesity with rapid or marked weight reduction, lean mass decline may account for up to 25–30% of total weight loss, while physiological lean loss typically accounts for roughly one-quarter of total weight loss.
- Trial body-composition data: STEP 1 semaglutide produced mean Δ body weight −14.9%, with ~34% of weight loss as lean mass and mean Δ lean mass −9.7%; SURMOUNT-1 tirzepatide produced mean Δ body weight −21.3%, with ~25% lean mass and mean Δ lean mass −10.9%; SUSTAIN-8 semaglutide produced mean Δ body weight −6%, with ~43% lean mass (calc) and mean Δ lean mass −4.5% (calc). SURPASS-3 MRI showed muscle volume decrease proportional to weight loss, with maintained fat-free muscle volume and improved muscle quality.
- Observational and meta-analytic evidence: a cross-sectional study of older adults on semaglutide reported 27.7% prevalence of reduced muscle mass; systematic reviews and meta-analyses found no independent detrimental effect on skeletal muscle index beyond expected proportional reductions, and physical performance outcomes were generally maintained.
- Prevention and pharmacology: recommended protein intake is 1.2–1.6 g/kg adjusted body weight/day, not below 0.4–0.5 g/kg/day, and prolonged intake ≥2 g/kg/day should be avoided; however, only 43% of GLP-1RA users met 1.2 g/kg/day and <10% reached 1.6–2.0 g/kg/day. In the phase II COURAGE trial interim analysis, trevogrumab plus semaglutide reduced lean mass by 3.3% versus 6.5% with semaglutide alone; no pharmacologic agent is standard of care.
Methods
- Narrative review including all English-language studies on muscle mass loss during GLP-1RA therapy in type 2 diabetes and obesity from major scientific databases and clinical trial registries.
- Synthesizes epidemiology and mechanisms of muscle loss, preventive and therapeutic strategies, and novel pharmacological approaches, with summary tables of main clinical trials and management strategies.
- No formal systematic review protocol, search dates, screening process, risk-of-bias assessment, or meta-analysis is reported.
Limitations
- Stated: the incidence of clinically significant muscle wasting attributable to GLP-1RA therapy remains undefined; trials have focused on weight and metabolic outcomes, lean mass reduction is typically a secondary endpoint, and most available studies lack direct assessments of muscle strength, physical performance, or gait speed.
- Stated: definitive randomized trials specifically designed to test protein, amino acid, and micronutrient supplementation in this population are lacking; pharmacologic agents lack consistent functional benefits and long-term safety data, and none is standard of care.
- Evident: as a narrative review, it does not report a systematic search strategy, study selection, quality appraisal, or quantitative synthesis, so conclusions rely on heterogeneous evidence and indirect comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
14 Valid · 0 Not valid · 46 Not checked · 23 Own results and interpretations
None of the sources cited for this claim have been checked yet.
In the paper
“Importantly, physical performance outcomes such as mobility and functional capacity are generally maintained, indicating that moderate lean mass loss during therapy does not necessarily equate to clinically relevant impairment [19, 26].”
§ Muscle loss and GLP-1R agonists use > Epidemiology
What the sources say
- Not checked yetcites [19] Scheen AJ (2025) GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies. Diabetes Metab 51(5):101681 source
- Could not verifycites [26] McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D et al (2020) Effects of once-weekly semaglutide vs once-daily Canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63(3):473–485 sourceExperimental — accuracy not yet measured
Our copy of the SUSTAIN 8 DXA substudy is complete and its endpoints are body-composition measures only: Results ('Change in total lean mass') report a 2.3 kg fall in total lean mass with semaglutide vs 1.5 kg with canagliflozin alongside a 1.2%-point rise in lean mass as a proportion of whole body, and the Discussion interprets these against other GLP-1RA/SGLT-2i DXA data. No passage reports or discusses physical performance, mobility, functional capacity, gait or grip strength, and the Discussion explicitly limits itself to DXA measurement issues (lean mass including organs, connective tissue and water) rather than functional outcomes. Searches for 'physical performance mobility functional capacity', 'grip strength sarcopenia', 'muscle strength physical function' and 'clinically relevant impairment' returned only body-composition passages and reference-list entries (e.g. refs 34, 41, 50 on strength/sarcopenia/aerobic capacity in other works), so the performance-maintenance inference attributed here cannot be checked against this paper. (LLM, conf=0.70)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary mechanism through which GLP-1RAs induce weight loss is appetite suppression and delayed gastric emptying, mediated via hypothalamic and brainstem pathways [27].”
§ Muscle loss and GLP-1R agonists use > Mechanisms of muscle loss associated with GLP-1RAs treatment
What the sources say
- Partly supportedcites [27] van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH (2014) Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 38(6):784–793 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) suggests that liraglutide-induced weight loss is mediated by reduced appetite and subsequent energy intake, and reports delayed gastric emptying during the first hour of a meal. It does not establish delayed gastric emptying as a primary cause of weight loss or identify hypothalamic and brainstem pathways. The study concerns liraglutide in obese adults without diabetes, not GLP-1 receptor agonists as a class. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Importantly, physical performance outcomes such as mobility and functional capacity are generally maintained, indicating that moderate lean mass loss during therapy does not necessarily equate to clinically relevant impairment [19, 26].”
§ Muscle loss and GLP-1R agonists use > Epidemiology
What the sources say
- Not checked yetcites [19] Scheen AJ (2025) GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies. Diabetes Metab 51(5):101681 source
- Could not verifycites [26] McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D et al (2020) Effects of once-weekly semaglutide vs once-daily Canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63(3):473–485 sourceExperimental — accuracy not yet measured
The Results report body-composition measurements, not mobility or functional capacity. The Discussion notes that DXA-measured lean mass includes non-muscle components, but does not establish whether physical performance was maintained during GLP-1RA therapy. Searches for mobility, functional capacity, physical performance, and muscle strength found no passage addressing that outcome. (LLM, conf=0.76)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Decreased insulin and IGF-1 signaling lowers mTOR activity, shifting the balance toward muscle catabolism [31].”
§ Muscle loss and GLP-1R agonists use > Mechanisms of muscle loss associated with GLP-1RAs treatment
What the sources say
- Supportedcites [31] Sartori R, Romanello V, Sandri M (2021) Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun 12(1):330 source
The Insulin/IGF1-AKT-mTOR section describes insulin and IGF1 as activators of the AKT–mTOR pathway, which promotes protein synthesis. Its Fig. 1 description says this signaling also inhibits protein breakdown, supporting the claim that decreased signaling shifts the balance toward catabolism. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In older adults with stable weight, supplementation with 3–4 g/day of eicosapentaenoic and docosahexaenoic acids for six months improved handgrip strength and lean mass [55].”
§ Muscle loss and GLP-1R agonists use > Prevention of muscle loss with dietary approach
What the sources say
- Partly supportedcites [55] Smith GI, Julliand S, Reeds DN, Sinacore DR, Klein S, Mittendorfer B (2015) Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. Am J Clin Nutr 102(1):115–122 sourceExperimental — accuracy not yet measured
The Participants section excludes people with unstable body weight, and Study design specifies 1.86 g EPA plus 1.50 g DHA daily for six months. The Results section reports improved handgrip strength and thigh muscle volume versus control, but it does not establish an increase in lean mass generally; that broader part of the claim is unsupported. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 6 with their cited sources checked
Create a free account to see all 83 claims and to verify the 51 references still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“caloric restriction (CR) and moderate weight loss (approximately 5–10%) improve insulin sensitivity despite the accompanying loss of muscle mass, and the observed reduction appears to result primarily from increased proteolysis rather than reduced protein synthesis.”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [84]
In the citing paper
“Although GLP-1RA therapy facilitates mobility through weight loss, particularly in older adults, maintaining exercise and physical activity can be challenging due to side effects and fatigue; moreover, low mechanical loading may increase the risk of lean mass loss [84].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [84]
In the citing paper
“Although GLP-1RA therapy facilitates mobility through weight loss, particularly in older adults, maintaining exercise and physical activity can be challenging due to side effects and fatigue; moreover, low mechanical loading may increase the risk of lean mass loss [84].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [84]
In the citing paper
“GLP-1 RA therapy, when combined with tailored resistance exercise and CR with dietary counseling, may be effective in preserving muscle mass and function by optimizing body composition changes [84].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [84]
In the citing paper
“Although GLP-1RA therapy facilitates mobility through weight loss, particularly in older adults, maintaining exercise and physical activity can be challenging due to side effects and fatigue; moreover, low mechanical loading may increase the risk of lean mass loss [84].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Muscle loss and GLP-1R agonists use > Novel pharmacological approaches
“PTT-A (novel unimolecular peptide tetra-agonist targeting GLP-1, GIP, glucagon and amylin receptors)”
§ Muscle loss and GLP-1R agonists use > References
“A novel unimolecular peptide Tetra-agonist (PTT-A) targeting GLP-1, GIP, Amylin, and calcitonin receptors”
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“A progressive decline in skeletal muscle mass and strength, or sarcopenia, is increasingly recognized as a significant comorbidity in patients with type 2 diabetes mellitus (T2D) and obesity [1, 2].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“In the STEP 1 trial, semaglutide produced substantial weight loss, of which approximately 30% was attributed to lean tissue, while fat loss predominated [21, 22 ].”
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048 · cited 1×
“In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as cornerstone therapies in the management of T2D and obesity [5–7 ].”
Mechanisms of muscle atrophy and hypertrophy: implications in health and disease
Sartori, R., Romanello, V., & Sandri, M. (2021) · Nature Communications · doi:10.1038/s41467-020-20123-1 · Cited by 940 · cited 3×
“Decreased insulin and IGF-1 signaling lowers mTOR activity, shifting the balance toward muscle catabolism [31].”
InfluentialVitamin D for the prevention of disease: An Endocrine Society clinical practice guideline
Demay, M. B., Pittas, A. G., Bikle, D. D., Diab, D. L., Kiely, M. E., Lazaretti-Castro, M., Lips, P., Mitchell, D. M., Murad, M. H., Powers, S., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae290 · Cited by 639
Breen, L., & Phillips, S. M. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-68 · Cited by 576 · cited 1×
“Age-related anabolic resistance diminishes the muscle-preserving effects of protein intake and exercise during weight loss [36].”
Esmarck, B., Andersen, J. L., Olsen, S., Richter, E. A., Mizuno, M., & Kjær, M. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00301.x · Cited by 540 · cited 1×
“…during GLP1RAs therapy is multifactorial, involving reduced protein intake and negative energy balance, hormonal adaptations, impaired mTOR signaling and protein synthesis, training program in old men, induced significant quadriceps hypertrophy, whereas delayed supplementation had no effect [ 48 ].”
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“The primary mechanism through which GLP-1RAs induce weight loss is appetite suppression and delayed gastric emptying, mediated via hypothalamic and brainstem pathways [27].”
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536
Fish oil–derived n−3 PUFA therapy increases muscle mass and function in healthy older adults
Smith, G. I., Julliand, S., Reeds, D. N., Sinacore, D. R., Klein, S., & Mittendorfer, B. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.105833 · Cited by 507 · cited 1×
“In older adults with stable weight, supplementation with 3–4 g/day of eicosa-pentaenoic and docosahexaenoic acids for six months improved handgrip strength and lean mass [55].”
Research works printed but not linked: 1
- Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at 61st EASD Annual Meeting 2025, Wien [press release]
Cited by
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“GLP-1 RA therapy, when combined with tailored resistance exercise and CR with dietary counseling, may be effective in preserving muscle mass and function by optimizing body composition changes [ 84].”
Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy
Belančić, A., Skroče, K., Gkrinia, E. M. M., Glavić, M. M., & Kwok, M. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155870 · Cited by 3
“Practical implementation should focus on individualized protein targets, meal distribution, tolerability, renal function, dietary preferences, and reassessment when appetite suppression limits adequate intake [74–78 ,80, 81 ].”
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Pardali, E. C., Gkouskou, K. K., Cholevas, C., Poulimeneas, D., Tsiroukidou, K., Goulis, D. G., & Grammatikopoulou, M. G. (2026) · Nutrients · doi:10.3390/nu18060962 · Cited by 6
“…concerns regarding possible reductions in lean body mass. Rapid weight loss, insufficient protein intake, and inadequate resistance activity may amplify this effect, underscoring the need for nutritional strategies that actively preserve muscle and skeletal integrity during therapy [64–66].”
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“Lean-tissue responses to pharmacologically induced weight loss may vary according to baseline body composition, age, metabolic status, and pre-existing sarcopenic risk [212,217,218].”
Metadata
- Authors
- Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P.
- Affiliations
- University of Milan (IT)
- Brigham and Women's Hospital (US)
- Corresponding author
- Fiorina, Paolo
- Venue
- Acta Diabetologica
- Published
- 2025-11-07
- Volume
- 63
- Issue
- 2
- Pages
- 333-342
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- PMC
- PMC12957034
- OpenAlex
- W4415987720
- Cited by
- 31
- References
- 74
- Citations by year
- 2026: 31
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Diabetologica (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca (20229ZA2YF)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- sarcopenia, skeletal muscle atrophy, GLP-1 receptor agonists, type 2 diabetes, obesity, lean mass loss, weight loss, insulin resistance, chronic inflammation, mitochondrial dysfunction, muscle protein metabolism, sarcopenia prevention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Muscle, Skeletal, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Muscle loss and GLP-1R agonists use. https://app.cochat.ai/papers/10.1007/s00592-025-02611-2
- The paper
- Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025). Muscle loss and GLP-1R agonists use. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02611-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.